CollPlant Biotechnologies (NASDAQ:CLGN) Given Buy Rating at D. Boral Capital

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $14.00 price objective on the stock. D. Boral Capital’s target price points to a potential upside of 273.33% from the stock’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

CollPlant Biotechnologies Stock Performance

Shares of NASDAQ CLGN opened at $3.75 on Tuesday. CollPlant Biotechnologies has a 52-week low of $3.24 and a 52-week high of $6.75. The company’s 50 day moving average price is $3.90 and its 200-day moving average price is $4.33. The company has a market capitalization of $42.94 million, a P/E ratio of -2.44 and a beta of 0.86.

CollPlant Biotechnologies (NASDAQ:CLGN) last released its earnings results on Wednesday, November 27th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. During the same quarter last year, the business posted ($0.38) earnings per share. Analysts forecast that CollPlant Biotechnologies will post -1.44 earnings per share for the current year.

Institutional Investors Weigh In On CollPlant Biotechnologies

A number of large investors have recently bought and sold shares of CLGN. Villere ST Denis J & Co. LLC boosted its position in shares of CollPlant Biotechnologies by 24.4% during the 3rd quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after purchasing an additional 95,000 shares in the last quarter. Benjamin Edwards Inc. acquired a new position in CollPlant Biotechnologies during the 3rd quarter worth approximately $112,000. Finally, AMH Equity Ltd boosted its holdings in CollPlant Biotechnologies by 17.4% in the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock worth $419,000 after acquiring an additional 17,295 shares in the last quarter. 21.69% of the stock is currently owned by institutional investors and hedge funds.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.